A Randomized, Open-label Study to Evaluate the Safety and Efficacy of GX-188E, a DNA Therapeutic Vaccine Administered Intramuscularly by Electroporation, With GX-I7 Intravaginal Application or Imiquimod Topical Application in HPV16 and/or 18 Positive Patients With CIN3.
Phase of Trial: Phase I
Latest Information Update: 04 Jul 2017
At a glance
- Drugs GX 188E (Primary) ; GX I7 (Primary) ; Imiquimod (Primary)
- Indications Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Therapeutic Use
- 04 Jul 2017 New trial record